Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as the world’s first biosimilar of ranibizumab, it promised to transform retinal disease treatment in India through affordability. A decade later, the anti-VEGF market has been fundamentally altered, with multiple biosimilars challenging multinational innovator dominance. This article examines Razumab’s trajectory through three phases: regulatory navigation, clinical…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
